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Diabetic neuropathy is a common complication of diabetes mellitus. Effective blood glucose control retards
changes in nerve conduction velocity in type 1 diabetes. This study examined the relationship between
glycemic control and electrophysiologic changes in diabetic neuropathy in 57 type 2 diabetic patients. Nerve
conduction in the peroneal motor nerve, tibial motor nerve, and sural nerve were measured at study entry
and at follow-up 24 ± 3.12 months later. Changes in individual nerves are expressed as a percentage change
(PC) and overall electrophysiologic changes are expressed as the sum of individual PCs. The PCs for
peroneal motor nerve velocity, tibial motor nerve velocity, and sural nerve velocity were all lower in patients
with a mean HbA1c of 8.5% or less compared with those in patients with a mean HbA1c of more than
8.5%, and SPCV (sum of PC in velocity) was significantly inversely correlated with mean HbA1c. However,
there was no significant difference in SPCV in subjects with or without hypertension, hypertriglyceridemia,
or low high-density lipoprotein cholesterol concentration. In conclusion, hyperglycemia is the most
important etiology for electrophysiologic progression in type 2 diabetic patients. Furthermore, a mean
HbA1c of more than 8.5% will result in significant deterioration in electrophysiology.
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Diabetic neuropathy is a common complication of diabetes
mellitus, affecting an estimated 50–60% of diabetic patients
[1–3]. It may result in sensory, motor, autonomic, or com-
bined deficits. Sensorimotor diabetic peripheral polyneu-
ropathy is a major risk factor for foot trauma, ulceration,
Charcot’s arthropathy, and limb amputation. The patho-
genesis of diabetic neuropathy has not been fully eluci-
dated. However, chronic hyperglycemia with its metabo-
lic consequences may be the most important factor [4,5].
Many studies have found a positive relationship between
hyperglycemia and the progression of diabetic neuropathy
in type 1 diabetic patients, and effective control of diabetes
has beneficial effects on electrophysiology in these patients
[6–8]. However, few studies focus on diabetic neuropathy
in type 2 diabetic patients, who account for more than 90%
of all cases of diabetes mellitus. There are several differences
between the neuropathy associated with type 1 and type 2
diabetes. In neuropathy of type 2 diabetes, a broader range
of fiber types is involved, and it is likely to have features of
covert or overt multifocality [9].
Sima and co-workers examined sural nerve biopsies
obtained from type 1 and type 2 diabetic patients with distal
symmetrical polyneuropathy [10]. They demonstrated that
degrees of nerve fiber loss, paranodal swelling and para-
nodal demyelination, and disintegration of the axons with
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breakdown of their myelin sheaths (Wallerian degeneration)
were significantly more prevalent in type 2 diabetes, where-
as in type 1 diabetes, axo-glial dysfunction was increased.
The histopathologic differences between the neuropathy
associated with type 1 and type 2 diabetes suggest that
there may be differences in pathogenesis. Therefore, it is
not inevitable that each type of neuropathy will respond
in the same manner to strict control of blood glucose
concentrations.
Many methods are used to assess and stage diabetic
neuropathy. Standard electrophysiologic methods have
been used extensively to diagnose and follow the progres-
sion of diabetic neuropathy [11] and correlate reliably with
neuropathic complications (foot ulcers and amputation)
and mortality [12]. The aim of this study was to investigate
the relationship between glycemic control and electro-
physiologic changes of diabetic neuropathy in type 2 dia-
betic patients.
MATERIALS AND METHODS
Subjects
Fifty-seven type 2 diabetic patients with diabetic neuropathy
were recruited. Diabetic neuropathy was diagnosed on the
basis of abnormalities in two of the four following major
categories: symptoms, signs, nerve conduction studies, and
quantitative sensory testing [7]. All patients had electro-
physiologic abnormalities at the beginning of follow-up.
There was no evidence of alcohol abuse or toxin exposure in
any patient. Patients with peripheral neuropathy principally
from causes other than diabetes, such as liver, renal, or
orthopedic disease or endocrine or metabolic disorders,
were excluded. Patients were recruited and followed-up by
the same two investigators in the outpatient clinic. Ten
patients were treated with twice-daily injections of insulin
and the others were treated with only oral anti-diabetic
drugs at the beginning of follow-up.
Electrophysiology study
Nerve conduction studies were performed using an elec-
trodiagnostic machine (Keypoint version 2.11, Medtronic
Dantec, Skovlunde, Denmark) by the same technician under
isothermal conditions in order to maintain the skin tem-
perature at 30°C. Action potentials were recorded using
surface electrodes. Nerve conduction in the peroneal motor
nerve, tibial motor nerve, and sural nerve was measured in
the conventional manner [13]. The mean values of bilateral
nerve conduction velocity and amplitude from each tested
nerve were used. Nerve conduction was measured at the
initial examination and at follow-up 24 ± 3.12 months later
(mean ± standard deviation; range, 15–28 months). Patients
were excluded if they had unobtainable nerve electric
responses in two investigations.
Changes in electrophysiology
The changes in individual nerves were first expressed as the
percentage change (PC, %) calculated using the formula:
PC = (Conduction velocity at follow-up) – (Initial conduction
velocity)/Initial conduction velocity × 100%
The overall electrophysiologic change was then
expressed as the sum of the individual PCs (%).
Laboratory examination
Blood glucose was monitored by measuring stable
glycosylated hemoglobin levels (HbA1c, %) at every 3-
month visit. The mean of all measurements was used for
statistical analysis.
Statistical analysis
All analysis was conducted using SPSS version 12.0 (SPSS
Inc, Chicago, IL, USA). The Mann-Whitney U test was used
for comparisons between groups. Linear regression was
used for establishing the relationship between the mean
HbA1c and electrophysiologic changes. The difference was
significant when p was less than 0.05.
RESULTS
Demographic data of the 57 patients are shown in Table 1.
Ages ranged from 38 to 82 years and the duration of diabe-
tes was between 2 and 38 years. The initial HbA1c varied
from 4.87% to 16.89%. Nine patients had hypertriglycer-
idemia (> 200 mg/dL) and 32 patients had low high-
density lipoprotein (HDL) cholesterol (< 40 mg/dL) at the
beginning of the study.
We divided patients into four subgroups according to
the mean HbA1c: Group I, mean HbA1c less than 7%;
Group II, mean HbA1c 7.01–7.5%; Group III, mean HbA1c
7.51–8.5%; and Group IV, mean HbA1c more than 8.5%. The
PC of peroneal motor nerve velocity was significantly worse
in patients in Group IV (–16.87%) than those in Groups I
(–6.09%), II (–1.73%), and III (–8%) (Table 2). Similarly, the
PC of tibial motor nerve velocity and sural nerve velocity
were both significantly lower in patients in Group IV
(–10.28% vs –0.09%, 5.39%, and 1.37%; –14.28% vs 2.29%,
4.4%, and 1.17%, respectively). The PC of peroneal motor
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nerve amplitude, tibial motor nerve amplitude, and sural
nerve amplitude were not significantly different between
subgroups (Table 3).
In Groups I–III, the sum of percentage change in velocity
(SPCV) was significantly lower than in Group IV, but there
was no significant difference in the sum of percentage
change in amplitude (SPCA) (Table 4).
The correlation of SPCV with mean HbA1c is shown in
the Figure. SPCV was significantly inversely correlated
with mean HbA1c: SPCV = –14.41(mean HbA1c) + 101.71
(R2 = 0.72, p = 0.001).
The comparison of SPCV in patients with other
underlying diseases is shown in Table 5. There was no
significant difference in subgroups with or without
hypertension, hypertriglyceridemia, and low HDL
cholesterol.
DISCUSSION
The deterioration in nerve conduction velocity was marked
in patients with a mean HbA1c of more than 8.5% during
a 2-year period. This downward trend was also noted in
nerve conduction amplitude with increases in mean HbA1c.
These results support the theory that hyperglycemia repre-
sents an important factor in the pathogenesis of diabetic
neuropathy in type 2 diabetes. The result is analogous to
the findings in type 1 diabetes [8,14]. Amthor et al found a
significant reduction in nerve conduction velocities during
an 8-year period in type 1 diabetic patients with a mean
HbA1c of more than 10% [8]. Tkac and Bril also showed that
diabetic neuropathy is more severe in diabetic patients with
an HbA1c of more than 9% [7]. This implies the progression
of diabetic neuropathy in type 2 diabetes, as well as in type
Table 1. Demographic characteristics of 57 patients with
diabetic neuropathy
Sex (male/female) 21/36
Mean age (yr) 61.41 ±  10.02
Mean duration of diabetes (yr) 9.85 ±  7.19
Mean interval between NCV study (mo) 24.33 ±  3.12
Mean HbA1c (%) 7.84 ±  1.21
Mean initial HbA1c (%) 7.86 ±  2.01
Hypertension 29
Hypertriglyceridemia 9
Low HDL level 32
Data are presented as mean ± standard deviation or n. NCV = nerve
conduction velocity; HbA1c = serum glycosylated hemoglobin
level; HDL = high-density lipoprotein.
1 diabetes.
Direct morphologic evaluation of nerves via whole nerve
biopsy has been used as an important tool for diagnosis and
evaluation of the progression of diabetic neuropathy [15].
However, full fascicular biopsy is associated with long-
term sensory deficits and other adverse effects. Furthermore,
there is a strong correlation between morphologic changes
in sural nerve biopsies and nerve conduction velocity, and
conventional electrophysiologic tests in lower limbs are a
reliable surrogate measure for structural abnormalities [16].
We found that maintaining the mean HbA1c below 8.5%
retards the deterioration of both motor and sensory nerve
conduction velocity in the lower limbs of type 2 diabetic
patients. Therefore, retarding changes in nerve conduction
velocity in the present study may reflect retarding structur-
al changes. Lower limb motor nerve conduction velocity
can predict foot ulceration and death in diabetes [12]. We
found that conduction velocity progression was inversely
correlated with mean HbA1c. Therefore, a lower mean
HbA1c that prevents the deterioration of motor nerve
velocity may contribute to reducing foot ulceration and
death in diabetes.
Some patients with a mean HbA1c of less than 8.5% in
the present study showed improvement in conduction
velocity due to a higher initial HbA1c than their mean
HbA1c. Several studies have found improvement in nerve
conduction velocity after treatment for diabetes [13].
Thomas concluded that patients with newly diagnosed or
poorly controlled diabetes frequently have reduced nerve
conduction velocity that improves rapidly with the estab-
lishment of euglycemia [17].
Some studies have observed other risk factors correlat-
ed to the severity of diabetic neuropathy [7,18,19], such as
hypertension, hypertriglyceridemia, and low HDL choles-
terol concentration. However, SPCV was not significantly
different in subjects with or without hypertension, hypertri-
glyceridemia, and low HDL cholesterol concentration in the
present study. This demonstrated that hyperglycemia, which
is directly related to myo-inositol loss and sorbitol excess
[20–22], is the major factor in electrophysiologic progression
in type 2 diabetes.
There was no significant difference in amplitude changes
between patients with mean HbA1c of 8.5% or less and
those with a mean HbA1c of more than 8.5%. This may have
resulted from the small difference in speed and amplitude
deterioration. Differences in amplitude may take longer to
become evident in type 2 diabetes. Velocity changes may be
a more sensitive index than amplitude changes for the
evaluation of diabetic neuropathy in type 2 diabetes.
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In conclusion, there is a tendency toward deterioration of
diabetic neuropathy with poor blood glucose control in type 2
diabetes. Furthermore, a serum HbA1c of more than 8.5% will
result in significant deterioration in electrophysiology.
Figure. Relationship between sum of percentage change in velocity
(SPCV) and mean serum glycosylated hemoglobin level (HbA1c).
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Table 5. Sum of percentage change in velocity (SPCV) in subjects with and without hypertension, hypertriglyceridemia and
low high-density lipoprotein (HDL) cholesterol concentration
Hypertension Hypertriglyceridemia Low HDL cholesterol
With Without With Without With Without
(n = 29) (n = 28) (n = 9) (n = 48) (n = 32) (n = 25)
SPCV (%) –9.60 ±  23.45 –8.98 ±  23.29 –6.93 ±  15.22 –9.74 ±  24.47       –8.67 ±  23.25 –10.10 ±  23.51
p 0.949 0.948  0.701
Data are presented as mean ±  standard deviation.
Table 4. Sum of percentage change in velocity (SPCV) and
amplitude (SPCA) according to mean glycosylated
hemoglobin (HbA1c)
HbA1c ≤ 8.5%  HbA1c > 8.5% p
(n = 44) (n = 13)
SPCV (%) 0.19 ±  15.84 –41.43 ±  12.47 < 0.001
SPCA (%) –26.89 ±  18.93 –31.38 ±  14.37 0.493
Data are presented as mean ±  standard deviation.
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